Please login to the form below

Not currently logged in
Email:
Password:

ViiV

This page shows the latest ViiV news and features for those working in and with pharma, biotech and healthcare.

ViiV chalks up another win for two-drug HIV regimen

ViiV chalks up another win for two-drug HIV regimen

ViiV chalks up another win for two-drug HIV regimen. Treatment given just once a month matches triple oral therapy. ... It also gives ViiV another fillip in its long-standing battle for supremacy in the HIV market with arch-rival Gilead Sciences.

Latest news

More from news
Approximately 32 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • The race for an HIV ‘cure’ The race for an HIV ‘cure’

    GSK’s majority-owned ViiV Healthcare is the strongest challenger to Gilead’s 52% market share.

  • Stronger together Stronger together

    The top-down approach has certainly been in evidence at ViiV, the joint venture between GlaxoSmithKline, Pfizer and Shionogi, as its CEO Dominique Limet told the eyeforpharma audience. “ ... This year's survey of European patient groups marked the

  • Deal Watch December 2015 Deal Watch December 2015

    2, 075. BMS (HIV business). GSK (ViiV). Acquisition - asset. Acquisition of HIV product pipeline from BMS incl.

  • Understanding the patient ecosystem Understanding the patient ecosystem

    The continued success of the ViiV pharma group, which has three times now been deemed the most reputable and engaged pharma firm in the eyes of patient charities, also highlights how

  • Choices, choices: the rapidly evolving HIV treatment landscape Choices, choices: the rapidly evolving HIV treatment landscape

    With the recent launch of Triumeq from ViiV – whose owner, GSK, brought the first HIV treatment to market in the late 1980s – this looks set to change. ... Viiv's Triumeq is now following a similar pattern. Although it gained EU approval in September

More from intelligence
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest appointments

  • GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

    GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet. She will become CEO designate at the HIV-focused firm in January. ... He said: “ Establishing and then leading ViiV Healthcare for the past seven years has been an incredible honour and

  • Phil Golz appointed commercial director at HealthUnlocked Phil Golz appointed commercial director at HealthUnlocked

    Phil Golz appointed commercial director at HealthUnlocked. Moves from ViiV Healthcare to join the socialnetwork for health. ... He joins the company from ViiV Healthcare, where he was executive director, and prior to that he served as head of commercial

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics